Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Final results

September 3, 2019
Download  full announcement Renalytix AI plc (AIM: RENX), the AIM listed developer of artificial intelligence-enabled diagnostics for kidney disease, announces its inaugural final results for the period ended June 30, 2019. Operational highlights The U.S.

Notice of results

August 20, 2019
Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence clinical  in vitro  diagnostics for kidney disease, announces that it will release its preliminary results for the year ended 30 June 2019 on Tuesday, 3 September 2019.

Expansion of Chronic Kidney Disease Advisory Board

August 6, 2019
Download  full announcement Intended appointment of an additional Non-Executive Director Renalytix AI plc (AIM: RENX), a developer of artificial intelligence clinical  in vitro  diagnostics for kidney disease, announces the expansion of its core investigator group for lead product  KidneyIntelX  ™

Total Voting Rights

July 31, 2019
Download  full announcement For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following: As of 31 July 2019, the Company’s issued and fully paid share capital consists of 59,416,134 ordinary shares with a nominal value of £0.0025 each (“Ordinary

Thomas McLain Appointed as President and Chief Commercial Officer

July 29, 2019
Download  full announcement RenalytixAI Expands Leadership Team with Focus on Reimbursement ahead of roll-out of artificial intelligence clinical in vitro diagnostic KidneyIntelX  ™ RenalytixAI plc (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces

US Executive Order on Advancing American Kidney Health

July 12, 2019
Download  full announcement Renalytix AI welcomes US Administration’s dedication to advancing American kidney health Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, welcomes the Executive Order signed by the President of the

FractalDx Positive Results Published in JASN

July 8, 2019
Download  full announcement Published data on blood diagnostic for subclinical acute kidney transplant rejection and potential to tailor immunosuppressive therapy Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces positive
Displaying 181 - 190 of 224